A comparison of stride parameters and carpal and tarsal joint angles during terrestrial and swimming locomotion in domestic dogs

In recent years, canine hydrotherapy has become increasingly popular to treat a range of conditions despite a lack of empirical evidence. It is currently unclear whether joint angles and limb movements performed by dogs during swimming are quantifiably beneficial for healthy animals. This study investigated the swimming kinematics of healthy dogs to establish baseline data for this activity and compare limb kinematics to that of overground locomotion. Kinematic data were recorded from eight healthy dolichocephalic dogs (mean age: 3.4±2.2) of a variety of breeds. Overground data were collected prior to swimming and consisted of dogs trotting on a flat surface. Swimming data were collected using an underwater camera during a standard hydrotherapy session conducted by a trained canine hydrotherapist. Range of motion, primarily due to an increase in flexion, was significantly greater (P<0.005) during swimming than trotting. Stride length (P<0.001) and frequency (P<0.005) were both significantly reduced in swimming compared to trot. Swimming kinematics recorded in this study are consistent with previously published data on canine aquatic locomotion but differ from those previously reported for water treadmill exercise. This study provides an insight into aquatic locomotion in healthy dogs indicating that range of motion exceeds that of terrestrial gaits. It is unclear whether these changes are beneficial for healthy animals and therefore further research is required to develop evidence-based protocols for industry practice.

Gene editing in CHO cells to prevent proteolysis and enhance glycosylation: Production of HIV envelope proteins as vaccine immunogens

Several candidate HIV subunit vaccines based on recombinant envelope (Env) glycoproteins have been advanced into human clinical trials. To facilitate biopharmaceutical production, it is necessary to produce these in CHO (Chinese Hamster Ovary) cells, the cellular substrate used for the manufacturing of most recombinant protein therapeutics. However, previous studies have shown that when recombinant Env proteins from clade B viruses, the major subtype represented in North America, Europe, and other parts of the world, are expressed in CHO cells, they are proteolyzed and lack important glycan-dependent epitopes present on virions. Previously, we identified C1s, a serine protease in the complement pathway, as the endogenous CHO protease responsible for the cleavage of clade B laboratory isolates of -recombinant gp120s (rgp120s) expressed in stable CHO-S cell lines. In this paper, we describe the development of two novel CHOK1 cell lines with the C1s gene inactivated by gene editing, that are suitable for the production of any protein susceptible to C1s proteolysis. One cell line, C1s-/- CHOK1 2.E7, contains a deletion in the C1s gene. The other cell line, C1s-/- MGAT1- CHOK1 1.A1, contains a deletion in both the C1s gene and the MGAT1 gene, which limits glycosylation to mannose-5 or earlier intermediates in the N-linked glycosylation pathway. In addition, we compare the substrate specificity of C1s with thrombin on the cleavage of both rgp120 and human Factor VIII, two recombinant proteins known to undergo unintended proteolysis (clipping) when expressed in CHO cells. Finally, we demonstrate the utility and practicality of the C1s-/- MGAT1- CHOK1 1.A1 cell line for the expression of clinical isolates of clade B Envs from rare individuals that possess broadly neutralizing antibodies and are able to control virus replication without anti-retroviral drugs (elite neutralizer/controller phenotypes). The Envs represent unique HIV vaccine immunogens suitable for further immunogenicity and efficacy studies.